Drug Approval | August 03, 2021
AYUSH 64 effective in mild and moderate COVID 19
It works as an adjunct to standard care based on robust clinical trials
It works as an adjunct to standard care based on robust clinical trials
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Subscribe To Our Newsletter & Stay Updated
